




RealRate

PHARMACEUTICAL 2026

Traverse Therapeutics Inc
Rank 115 of 178



The relative strengths and weaknesses of Traverse Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Traverse Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 49% points below the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	437,565	Assets	605,191
Cost of Goods Sold	10,339	Liabilities	490,363
Intangible Assets	113,868	Expenses	554,540
Liabilities, Current	159,904	Revenues	490,728
Liabilities, Non-Current	18,735	Stockholders Equity	114,828
Other Assets	49,736	Net Income	-25,546
Other Compr. Net Income	-1,109	Comprehensive Net Income	-26,100
Other Expenses	988	BaseVar	1,090,098
Other Liabilities	311,724	ECR before LimitedLiability	41%
Other Net Income	38,266	Economic Capital Ratio	180%
Other Revenues	490,728		
Property and Equipment	4,022		
Research and Development	206,011		
Selling, General and Administrative Expense	337,202		